ZVS 203e
Alternative Names: ZVS-203eLatest Information Update: 04 Jun 2023
At a glance
- Originator Chigenovo
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene transference; Rhodopsin expression inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase 0 Retinitis pigmentosa
Most Recent Events
- 12 Sep 2023 Phase-0 for Retinitis pigmentosa in China (Intraocular, Injection) (NCT05805007)
- 07 Apr 2023 Peking University Third Hospital plans an early phase I trial for Retinitis pigmentosa in unknown location (Intraocular, Injection) (NCT05805007)
- 01 Apr 2023 Preclinical trials in Retinitis pigmentosa in China (Intraocular, Injection) (Chigenovo pipeline, April 2023)